Gene Logic to search for secondary paths for Solvay pipeline
GAITHERSBURG, Md. Gene Logic will be seeking different development paths for multiple Solvay Pharmaceutical drug candidates that were discontinued or deprioritized in clinical trials for reasons other than safety. The two companies have entered into a drug repositioning and development agreement.
As a result of the agreement, any drug candidate that Gene Logic finds a new use for may give the company an exclusive license for that drug, if Solvay chooses not to develop it. Solvay, manufacturer of Creon, would be entitled though to royalty and milestone payments if Gene Logic gets the license.
Gene Logic has said that, “its drug repositioning program seeks to find alternate development paths for drug candidates with good safety records that have been deprioritized or discontinued in clinical trials.”
Teva receives final FDA approval for generic Famvir, but will delay marketing until patent hearing
JERUSALEM Teva Pharmaceuticals has been granted final approval on its application to market famciclovir, the generic version of Novartis’ Famvir in the 125, 250 and 500mgs.
Now with the approval from the Food and Drug Administration, Teva is also awarded a 180-day period of market exclusivity. But the company will hold off marketing the item until at least Sept. 5, 2007.
On that day, a hearing will be held involving a patent infringement suit brought against Teva regarding the famciclovir. The hearing is scheduled to meet at the U.S. District Court for the District of New Jersey regarding Novartis’ motion for a preliminary injunction. Therefore, both parties have agreed to not launch a generic version of Famvir until after the hearing.
Forest, Daiichi Sankyo sign agreement for Azor
NEW YORK Forest Laboratories and Daiichi Sankyo have signed a co-promotional agreement for Daiichi Sankyo’s new antihypertension drug Azor. Azor is a combination of the calcium channel blocker amlodipine besylate and the angiotensin receptor blocker olmesartan medoxomil.
Under the agreement, Forest will pay Daiichi Sankyo an upfront payment of $20 million and will receive a payment based upon product sales. The agreement is for three years, after which, Daiichi Sankyo will make residual payments to Forest.
The drug is still under review by the Food and Drug Administration with a decision expected by late September. Hypertension affects roughly 72 million people in the U.S., with about 65 percent of those diagnosed having trouble keeping it under control.